Ultime notizie per RAPT Therapeutics (NASDAQ:RAPT) Azioni

RAPT Therapeutics

RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.

RAPT Therapeutics Inc

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Alnylam Pharma (ALNY – Research Report), RAPT Ther...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Alnylam Pharma (ALNY), RAPT Therapeutics (RAPT) and Liquidia Technologies (LQDA)

Q3 pharma and biotech layoffs in charts: More than 1000 each in July and August

Warning: RAPT is at high risk of performing badly

RAPT Therapeutics (RAPT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Yanan Zhu from...

Promising Risk-Reward Scenario for RAPT Therapeutics: A Buy Rating Amid Clinical Uncertainties and Valuation Considerations

ABUS

ALNY

ALPMF

ALPMY

ANTX

ATHA

BAYRY

BAYZF

BBIO

BMRN

CDTX

CRBU

CVAC

FGEN

GLYC

HLVX

IBRX

INAB

LQDA

LXRX

PGEN

QURE

RAPT

RHHBY

RLAY

RPTX

SLRN

VIRX

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of RAPT Therapeutics, Inc. - RAPT

Press Releases

RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients

Earnings

RAPT Therapeutics Reports First Quarter 2024 Financial Results

News

Legal

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against RAPT Therapeutics, Inc. and Encourages Investors to Contact the Firm

RAPT Therapeutics Reports Second Quarter 2024 Financial Results

Agenus

Aileron Therapeutics, Inc. - Common Stock

Aileron Therapeutics

ALX Oncology Holdings Inc. - Common Stock

ALX Oncology Holdings

Adlai Nortye Ltd. - American Depositary Shares

Adlai Nortye

Armata Pharmaceuticals, Inc. Common Stock

Armata Pharmaceuticals

Aerovate Therapeutics, Inc. - Common Stock

Aerovate Therapeutics

Biodexa Pharmaceuticals plc - American Depositary Shares

Biodexa Pharmaceuticals

BeyondSpring

Coherus BioSciences

Cellectar Biosciences, Inc. - Common Stock

Cellectar Biosciences

Chimerix

CytomX Therapeutics

Citius Oncology

DBV Technologies S.A. - American Depositary Shares

DBV Technologies

I-MAB

IO Biotech

MAIA Biotechnology

Metagenomi

MediciNova

Ovid Therapeutics

PMV Pharma

Quince Therapeutics

SELLAS Life Sciences Group, Inc. - Common Stock

SELLAS Life Sciences Gr

Spero Therapeutics

Vistagen Therapeutics, Inc. - Common Stock

Vistagen Therapeutics

Barclays

JP Morgan

Leerink Partners

Berenberg

Comments

RAPT Therapeutics

Notizie

Ultime notizie per RAPT Therapeutics (NASDAQ:RAPT) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO